Patents by Inventor Yingxiao Wang

Yingxiao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230233607
    Abstract: In alternative embodiments, provided are compositions, including recombinant expression systems and vectors, products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells such as T cells in vivo, for example, activating, adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for the control of therapeutic outcomes.
    Type: Application
    Filed: February 17, 2021
    Publication date: July 27, 2023
    Inventors: Yingxiao WANG, Ziliang HUANG, Yiqian WU
  • Patent number: 11667900
    Abstract: Provided are Shp2- and Spleen tyrosine kinase (Syk)-integrated sensing and actuating protein (iSNAP) (Shp2- and Syk-iSNAP) chimeric proteins comprising: a bi-phosphorylatable peptide, optionally a bisphosphoryl tyrosine-based activation (BTAM) motif; a Fluorescent Protein (FP) Förster Resonance Energy Transfer (FRET) (or FP FRET) pair or pair of motifs; a truncated Shp2 domain comprising an N-Src Homology 2(N-SH2) domain and a C-Src Homology 2(C-SH2) domain; and, a phosphatase (PTP) domain or a kinase domain. Provided are engineered cells and methods for cancer cell or tumor eradication, or for the treatment or amelioration of a cancer, tumor or dysfunctional cell, or for promoting an anti-cancer, anti-tumor or anti-dysfunctional cell inflammatory response, including enhancing macrophage-, monocyte-, microglia-, osteoclast-, Kupffer cell- or dendritic cell-mediated antibody- or monoclonal antibody (mAb)-guided cancer or dysfunctional cell or tumor eradication, amelioration, or treatment.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: June 6, 2023
    Assignee: The Regents of the University of California
    Inventors: Yingxiao Wang, Shu Chien, Lei Lei, Shaoying Lu, Jie Sun
  • Publication number: 20230036060
    Abstract: Provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells such as a T cell, a primary T cell, a B cell, a monocyte, a macrophage, a dendritic cell or a natural killercell in vivo, for example, including activating, adding functions or changing or adding specificities for an immune cell, for monitoring physiologic processes, for the correction of pathological processes and for the control of therapeutic outcomes. Provided are tamoxifen-gated photoactivatable split-Cre recombinase optogenetic systems, called TamPA-Cre, that feature high spatiotemporal control to control or alter cell activities in vivo, for example, to limit the activity of a Chimeric Antigen Receptor (CAR)-expressing cell such as an immune cell and its activity at a tumor site for immunotherapy applications.
    Type: Application
    Filed: September 25, 2020
    Publication date: February 2, 2023
    Inventors: Yingxiao WANG, Molly E. ALLEN, Ziliang HUANG
  • Patent number: 11504427
    Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells, e.g., adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for control of therapeutic outcomes. In alternative embodiments, provided are ultrasound-based thermal or mechanical stimulations, and thermo- or mechano-sensitive protein, either synthetically engineered or natively (endogenously) occurring, integrated to control the production of intracellular nucleic acid and gene expression, e.g., for the expression of biological-active proteins, which can be used, in alternative embodiments, for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Yingxiao Wang, Shu Chien, Yijia Pan, Yiqian Wu, Shaoying Lu, Kirk Shung
  • Publication number: 20220354891
    Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for engineering immune effector cells, e.g., T cells, NK cells, monocytes and/or macrophages to recognize and destroy a desired target cell, which can be a cancer cell, a dysfunctional cell, or an infected cell.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 10, 2022
    Inventors: Yingxiao WANG, Praopim LIMSAKUL, Yiqian WU
  • Publication number: 20220298515
    Abstract: Provided are compositions, products of manufacture, kits and methods for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells such as T cells in vivo, for activating, adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for the control of therapeutic outcomes. Provided are ultrasound-based stimulations and a heat-sensitive activation of proteins caused by the activation of polypeptides controlled by heat shock protein promoters to control the production of intracellular nucleic acid and gene expression, for example, for the expression of biological-active proteins such as T cell receptors, for example, chimeric antigen receptors (CARs).
    Type: Application
    Filed: September 10, 2020
    Publication date: September 22, 2022
    Inventors: Yingxiao WANG, Shu CHIEN, Yiqian WU, Shaoying LU
  • Publication number: 20200140834
    Abstract: Provided are Shp2- and Spleen tyrosine kinase (Syk)-integrated sensing and actuating protein (iSNAP) (Shp2- and Syk-iSNAP) chimeric proteins comprising: a bi-phosphorylatable peptide, optionally a bisphosphoryl tyrosine-based activation (BTAM) motif; a Fluorescent Protein (FP) Förster Resonance Energy Transfer (FRET) (or FP FRET) pair or pair of motifs; a truncated Shp2 domain comprising an N-Src Homology 2(N-SH2) domain and a C-Src Homology 2(C-SH2) domain; and, a phosphatase (PTP) domain or a kinase domain. Provided are engineered cells and methods for cancer cell or tumor eradication, or for the treatment or amelioration of a cancer, tumor or dysfunctional cell, or for promoting an anti-cancer, anti-tumor or anti-dysfunctional cell inflammatory response, including enhancing macrophage-, monocyte-, microglia-, osteoclast-, Kupffer cell- or dendritic cell-mediated antibody- or monoclonal antibody (mAb)-guided cancer or dysfunctional cell or tumor eradication, amelioration, or treatment.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 7, 2020
    Inventors: Yingxiao WANG, Shu CHIEN, Lei LEI, Shaoying LU, Jie SUN
  • Publication number: 20200108145
    Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells, e.g., adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for control of therapeutic outcomes. In alternative embodiments, provided are ultrasound-based thermal or mechanical stimulations, and thermo- or mechano-sensitive protein, either synthetically engineered or natively (endogenously) occurring, integrated to control the production of intracellular nucleic acid and gene expression, e.g., for the expression of biological-active proteins, which can be used, in alternative embodiments, for diagnostic or therapeutic purposes.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 9, 2020
    Inventors: Yingxiao WANG, Shu CHIEN, Yijia PAN, Yiqian WU, Shaoying LU, Kirk SHUNG
  • Patent number: 8192947
    Abstract: The present invention is a novel biosensor composed of mOrange2 and mCherry fluorescent proteins operably linked via a linker, which provides a distinct color change upon separation of the fluorescent proteins.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 5, 2012
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Yingxiao Wang, Mingxing Ouyang
  • Patent number: 8114581
    Abstract: Methods and compositions for identifying neoplastic cells in a biological sample are provided.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: February 14, 2012
    Assignee: The Regents of the University of California
    Inventors: Shu Chien, Yingxiao Wang
  • Publication number: 20110171675
    Abstract: The present invention is a novel FRET-based biosensor composed of ECFP and YPet fluorescent proteins operably linked via a MT1-MMP recognition sequence for use in the detection of cancer cells in a biological sample.
    Type: Application
    Filed: August 4, 2009
    Publication date: July 14, 2011
    Inventors: Yingxiao Wang, Shaoying Lu, Mingxing Ouyang
  • Publication number: 20100041087
    Abstract: The present invention is a novel biosensor composed of mOrange2 and mCherry fluorescent proteins operably linked via a linker, which provides a distinct color change upon separation of the fluorescent proteins.
    Type: Application
    Filed: October 12, 2007
    Publication date: February 18, 2010
    Inventors: Yingxiao Wang, Mingxing Ouyang
  • Publication number: 20090305309
    Abstract: Methods and compositions for identifying neoplastic cells in a biological sample are provided.
    Type: Application
    Filed: September 15, 2006
    Publication date: December 10, 2009
    Applicant: The Regents of the University of California
    Inventors: Shu Chien, Yingxiao Wang